Study conducted by the Institute of Child Care Research at Queens College of Sociology.

Of those who had taken cocaine, only one in ten utilized it on a weekly basis. This means that that while some teenagers have experimented with the medication, few continue steadily to use it regularly. ‘While cocaine has only recently emerged to the Northern Ireland drug scene, this study shows that it might be producing its way into the adolescent drug scene quite quickly. It indicates that the profile of cocaine users could be changing also. ‘In the 1990’s the typical cocaine user was one, within their twenties, well-educated, and in a well-paid professional work.

That meant the drug was officially illegal and users will be prosecuted now. And that’s the way it had been on Wednesday, 17 April, 1985.

Advaxis reviews continued positive individual survival pattern in ADXS-HPV Phase 2 cervical cancer trial Advaxis, Inc., , a head in developing another generation of immunotherapies for malignancy and infectious illnesses, presented up to date preliminary data from an ongoing randomized Phase 2 trial of ADXS-HPV being conducted in India in females with recurrent/refractory cervical malignancy who have failed prior cytotoxic therapy. These data were reported on Thursday, July 26, 2015 at the Immunotherapy Subcommittee Workshop of the Gynecologic Oncology Group conference in Boston.That meant the drug was officially illegal and users will be prosecuted now. And that’s the way it had been on Wednesday, 17 April, 1985.

Advaxis reviews continued positive individual survival pattern in ADXS-HPV Phase 2 cervical cancer trial Advaxis, Inc., , a head in developing another generation of immunotherapies for malignancy and infectious illnesses, presented up to date preliminary data from an ongoing randomized Phase 2 trial of ADXS-HPV being conducted in India in females with recurrent/refractory cervical malignancy who have failed prior cytotoxic therapy. These data were reported on Thursday, July 26, 2015 at the Immunotherapy Subcommittee Workshop of the Gynecologic Oncology Group conference in Boston.